Literature DB >> 17116756

Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways.

Walkyria Oliveira Sampaio1, Robson Augusto Souza dos Santos, Raphael Faria-Silva, Leonor Tapias da Mata Machado, Ernesto L Schiffrin, Rhian M Touyz.   

Abstract

Angiotensin-(1-7) [Ang-(1-7)] causes endothelial-dependent vasodilation mediated, in part, by NO release. However, the molecular mechanisms involved in endothelial NO synthase (eNOS) activation by Ang-(1-7) remain unknown. Using Chinese hamster ovary cells stably transfected with Mas cDNA (Chinese hamster ovary-Mas), we evaluated the underlying mechanisms related to receptor Mas-mediated posttranslational eNOS activation and NO release. We further examined the Ang-(1-7) profile of eNOS activation in human aortic endothelial cells, which constitutively express the Mas receptor. Chinese hamster ovary-Mas cells and human aortic endothelial cell were stimulated with Ang-(1-7; 10(-7) mol/L; 1 to 30 minutes) in the absence or presence of A-779 (10(-6) mol/L). Additional experiments were performed in the presence of the phosphatidylinositol 3-kinase inhibitor wortmannin (10(-6) mol/L). Changes in eNOS (at Ser1177/Thr495 residues) and Akt phosphorylation were evaluated by Western blotting. NO release was measured using both the fluorochrome 2,3-diaminonaphthalene and an NO analyzer. Ang-(1-7) significantly stimulated eNOS activation (reciprocal phosphorylation/dephosphorylation at Ser1177/Thr495) and induced a sustained Akt phosphorylation (P<0.05). Concomitantly, a significant increase in NO release was observed (2-fold increase in relation to control). These effects were blocked by A-779. Wortmannin suppressed eNOS activation in both Chinese hamster ovary-Mas and human aortic endothelial cells. Our findings demonstrate that Ang-(1-7), through Mas, stimulates eNOS activation and NO production via Akt-dependent pathways. These novel data highlight the importance of the Ang-(1-7)/Mas axis as a putative regulator of endothelial function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116756     DOI: 10.1161/01.HYP.0000251865.35728.2f

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  161 in total

1.  Angiotensin-(1-7) suppresses the number and function of the circulating fibrocytes by upregulating endothelial nitric oxide synthase expression.

Authors:  Kan Wang; Xiaosheng Hu; Changqing Du; Shike Tu; Furong Zhang; Xudong Xie
Journal:  Mol Cell Biochem       Date:  2012-03-29       Impact factor: 3.396

2.  Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide.

Authors:  Tanya M Gwathmey; Brian M Westwood; Nancy T Pirro; Lijun Tang; James C Rose; Debra I Diz; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-01

3.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

4.  C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway.

Authors:  Qijun Zheng; Yuexing Yuan; Wei Yi; Wayne Bond Lau; Yajing Wang; Xiaoliang Wang; Yang Sun; Bernard L Lopez; Theodore A Christopher; Jonathan M Peterson; G William Wong; Shiqiang Yu; Dinghua Yi; Xin-Liang Ma
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

Review 5.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

6.  ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response.

Authors:  Yue-Hui Zhang; Yong-huan Zhang; Xue-Fei Dong; Qing-Qing Hao; Xiao-Ming Zhou; Qing-Tao Yu; Shu-Ying Li; Xu Chen; Abdulai Fallah Tengbeh; Bo Dong; Yun Zhang
Journal:  Inflamm Res       Date:  2015-02-27       Impact factor: 4.575

7.  Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2.

Authors:  Vaibhav B Patel; Abhijit Takawale; Tharmarajan Ramprasath; Subhash K Das; Ratnadeep Basu; Maria B Grant; David A Hall; Zamaneh Kassiri; Gavin Y Oudit
Journal:  J Mol Med (Berl)       Date:  2015-04-15       Impact factor: 4.599

Review 8.  Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data.

Authors:  Andrew M South; Hossam A Shaltout; Lisa K Washburn; Alexa S Hendricks; Debra I Diz; Mark C Chappell
Journal:  Clin Sci (Lond)       Date:  2019-01-08       Impact factor: 6.124

Review 9.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

10.  Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats.

Authors:  Karl D Pendergrass; Nancy T Pirro; Brian M Westwood; Carlos M Ferrario; K Bridget Brosnihan; Mark C Chappell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.